Emergent BioSolutions (NYSE:EBS) Cut to “Hold” at StockNews.com

Emergent BioSolutions (NYSE:EBS) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Friday.

Several other analysts also recently weighed in on EBS. Benchmark boosted their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Rodman & Renshaw reissued a “buy” rating and set a $16.00 price target on shares of Emergent BioSolutions in a research report on Friday, September 13th.

Emergent BioSolutions Stock Performance

Emergent BioSolutions stock opened at $8.10 on Friday. The firm has a fifty day simple moving average of $9.30 and a two-hundred day simple moving average of $8.80. Emergent BioSolutions has a twelve month low of $1.42 and a twelve month high of $15.10. The company has a market capitalization of $438.89 million, a PE ratio of -1.98 and a beta of 1.59. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in EBS. Meeder Asset Management Inc. purchased a new position in shares of Emergent BioSolutions during the second quarter valued at about $41,000. Verus Capital Partners LLC purchased a new position in shares of Emergent BioSolutions in the 2nd quarter valued at approximately $68,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Emergent BioSolutions in the second quarter worth $93,000. Stifel Financial Corp purchased a new position in Emergent BioSolutions during the third quarter valued at $96,000. Finally, Morse Asset Management Inc bought a new stake in shares of Emergent BioSolutions during the 2nd quarter valued at $97,000. 78.40% of the stock is owned by hedge funds and other institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.